Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, with 12,550 deaths resulting from the disease. Endometrial carcinoma includes pure endometrioid cancer and carcinomas with high-risk endometrial histology (including uterine serous carcinoma, clear cell carcinoma, carcinosarcoma [also known as malignant mixed Müllerian tumor], and undifferentiated/dedifferentiated carcinoma). Stromal or mesenchymal sarcomas are uncommon subtypes accounting for approximately 3% of all uterine cancers. This selection from the NCCN Guidelines for Uterine Neoplasms focuses on the diagnosis, staging, and management of pure endometrioid carcinoma. The complete version of the NCCN Guidelines for Uterine Neoplasms is available online at NCCN.org.
Individual Disclosures for the NCCN Uterine Neoplasms Panel
ObermairA, YouldenDR, YoungJP, et al.Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer2010;127:2678–2684.
ObermairA, YouldenDR, YoungJP, Risk of endometrial cancer for women diagnosed with HNPCC-related colorectal carcinoma. Int J Cancer 2010;127:2678–2684.20533284)| false
UedaSM, KappDS, CheungMK, et al.Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol2008;198:218.E1–E6.
UedaSM, KappDS, CheungMK, Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. Am J Obstet Gynecol 2008;198:218.E1–E6.18226630)| false
ChanJK, ShermanAE, KappDS, et al.Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol2011;29:832–838.
ChanJK, ShermanAE, KappDS, Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J Clin Oncol 2011;29:832–838.21263082)| false
Benedetti PaniciP, BasileS, SalernoMG, et al.Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. Am J Obstet Gynecol2014;210:363.E1–E10.
Benedetti PaniciP, BasileS, SalernoMG, Secondary analyses from a randomized clinical trial: age as the key prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 2014;210:363.E1–E10.24361787)| false
DollKM, TsengJ, DenslowSA, et al.High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol2014;132:44–49.
DollKM, TsengJ, DenslowSA, High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol 2014;132:44–49.24183734)| false
WangJ, XuP, YangX, et al.Association of myometrial invasion with lymphovascular space invasion, lymph node metastasis, recurrence, and overall survival in endometrial cancer: a meta-analysis of 79 studies with 68,870 patients. Front Oncol2021;11:762329.
WangJ, XuP, YangX, Association of myometrial invasion with lymphovascular space invasion, lymph node metastasis, recurrence, and overall survival in endometrial cancer: a meta-analysis of 79 studies with 68,870 patients. Front Oncol 2021;11:762329.34746002)| false
RaffoneA, TravaglinoA, RaimondoD, et al.Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma. Gynecol Oncol2021;162:401–406.
RaffoneA, TravaglinoA, RaimondoD, Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma. Gynecol Oncol 2021;162:401–406.34088515)| false
ResnickKE, HampelH, FishelR, et al.Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol2009;114:128–134.
ResnickKE, HampelH, FishelR, Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol 2009;114:128–134.19375789)| false
McAlpineJN, ChiuDS, NoutRA, et al.Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer2021;127:2409–2422.
McAlpineJN, ChiuDS, NoutRA, Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: an individual patient data meta-analysis. Cancer 2021;127:2409–2422.33793971)| false
JumaahAS, SalimMM, Al-HaddadHS, et al.The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis. J Pathol Transl Med2020;54:471–479.
JumaahAS, SalimMM, Al-HaddadHS, The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis. J Pathol Transl Med 2020;54:471–479.32867011)| false
TravaglinoA, RaffoneA, StradellaC, et al.Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups. Arch Gynecol Obstet2020;301:1355–1363.
TravaglinoA, RaffoneA, StradellaC, Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups. Arch Gynecol Obstet 2020;301:1355–1363.32296930)| false
BuchananDD, TanYY, WalshMD, et al.Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol2014;32:90–100.
BuchananDD, TanYY, WalshMD, Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing. J Clin Oncol 2014;32:90–100.24323032)| false
FergusonSE, AronsonM, PollettA, et al.Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer2014;120:3932–3939.
FergusonSE, AronsonM, PollettA, Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing. Cancer 2014;120:3932–3939.25081409)| false
GoodfellowPJ, BillingsleyCC, LankesHA, et al.Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for lynch syndrome screening in endometrial cancers from GOG210: an NRG oncology and Gynecologic Oncology Group study. J Clin Oncol2015;33:4301–4308.
GoodfellowPJ, BillingsleyCC, LankesHA, Combined microsatellite instability, MLH1 methylation analysis, and immunohistochemistry for lynch syndrome screening in endometrial cancers from GOG210: an NRG oncology and Gynecologic Oncology Group study. J Clin Oncol 2015;33:4301–4308.)| false
WatkinsJC, YangEJ, MutoMG, et al.Universal screening for mismatch- repair deficiency in endometrial cancers to identify patients with Lynch syndrome and Lynch-like syndrome. Int J Gynecol Pathol2017;36:115–127.
WatkinsJC, YangEJ, MutoMG, Universal screening for mismatch- repair deficiency in endometrial cancers to identify patients with Lynch syndrome and Lynch-like syndrome. Int J Gynecol Pathol 2017;36:115–127.27556954)| false
MillsAM, LiouS, FordJM, et al.Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol2014;38:1501–1509.
MillsAM, LiouS, FordJM, Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer. Am J Surg Pathol 2014;38:1501–1509.25229768)| false
RaffoneA, TravaglinoA, CerboneM, et al.Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res2020;26:1417–1427.
RaffoneA, TravaglinoA, CerboneM, Diagnostic accuracy of immunohistochemistry for mismatch repair proteins as surrogate of microsatellite instability molecular testing in endometrial cancer. Pathol Oncol Res 2020;26:1417–1427.32377987)| false
WinAK, LindorNM, WinshipI, et al.Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst2013;105:274–279.
WinAK, LindorNM, WinshipI, Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst 2013;105:274–279.23385444)| false
MeyerLA, BroaddusRR, LuKH. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control 2009;16:14–22.19078925)| false
JärvinenHJ, Renkonen-SinisaloL, Aktán-CollánK, et al.Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol2009;27:4793–4797.
JärvinenHJ, Renkonen-SinisaloL, Aktán-CollánK, Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 2009;27:4793–4797.19720893)| false
SchmelerKM, LynchHT, ChenLM, Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006;354:261–269.16421367)| false
SmithRA, BrooksD, CokkinidesV, et al.Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin2013;63:88–105.
SmithRA, BrooksD, CokkinidesV, Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013;63:88–105.23378235)| false
LeitaoMMJr, KehoeS, BarakatRR, et al.Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol2009;113:105–108.
LeitaoMMJr, KehoeS, BarakatRR, Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009;113:105–108.)| false
CrivellaroC, SignorelliM, GuerraL, et al.Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecol Oncol2013;130:306–311.
CrivellaroC, SignorelliM, GuerraL, Tailoring systematic lymphadenectomy in high-risk clinical early stage endometrial cancer: the role of 18F-FDG PET/CT. Gynecol Oncol 2013;130:306–311.23707673)| false
AntonsenSL, JensenLN, LoftA, et al.MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecol Oncol2013;128:300–308.
AntonsenSL, JensenLN, LoftA, MRI, PET/CT and ultrasound in the preoperative staging of endometrial cancer - a multicenter prospective comparative study. Gynecol Oncol 2013;128:300–308.23200916)| false
BollineniVR, Ytre-HaugeS, Bollineni-BalabayO, et al.High diagnostic value of 18F-FDG PET/CT in endometrial cancer: systematic review and meta-analysis of the literature. J Nucl Med2016;57:879–885.
BollineniVR, Ytre-HaugeS, Bollineni-BalabayO, High diagnostic value of 18F-FDG PET/CT in endometrial cancer: systematic review and meta-analysis of the literature. J Nucl Med 2016;57:879–885.26823564)| false
ReinholdC, UenoY, AkinEA, et al.ACR Appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer. J Am Coll Radiol2020;17(Suppl 11):S472–486.
PatsnerB, OrrJWJr, MannWJJr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol1990;162:427–429.
PatsnerB, OrrJWJr, MannWJJr. Use of serum CA 125 measurement in posttreatment surveillance of early-stage endometrial carcinoma. Am J Obstet Gynecol 1990;162:427–429.2309825)| false
RosePG, SommersRM, RealeFR, et al.Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol1994;84:12–16.
RosePG, SommersRM, RealeFR, Serial serum CA 125 measurements for evaluation of recurrence in patients with endometrial carcinoma. Obstet Gynecol 1994;84:12–16.8008305)| false
CreasmanWT, MorrowCP, BundyBN, et al.Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer1987;60(Suppl 8):2035–2041.
CreasmanWT, MorrowCP, BundyBN, Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60(Suppl 8):2035–2041.)| false
BenedetJL, BenderH, JonesHIII, et al.FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet2000;70:209–262.
BenedetJL, BenderH, JonesHIII, FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000;70:209–262.11041682)| false
MatsuoK, YabunoA, HomMS, et al.Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecol Oncol2018;149:301–309.
MatsuoK, YabunoA, HomMS, Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer. Gynecol Oncol 2018;149:301–309.29605499)| false
PetersEEM, León-CastilloA, SmitVT, et al.Defining substantial lymphovascular space invasion in endometrial cancer. Int J Gynecol Pathol2022;41:220–226.
RottmannD, SnirOL, WuX, et al.HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Mod Pathol2020;33:118–127.
LivasyCA, ReadingFC, MooreDT, et al.EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol2006;100:101–106.
YoshidaH, NishikawaT, MatsumotoK, et al.Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch2021;478:1161–1171.
YoshidaH, NishikawaT, MatsumotoK, Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Arch 2021;478:1161–1171.33423127)| false
JenkinsTM, CantrellLA, StolerMH, et al.HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology. Am J Surg Pathol2022;46:435–442.
JenkinsTM, CantrellLA, StolerMH, HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology. Am J Surg Pathol 2022;46:435–442.35125452)| false
AliA, BlackD, SoslowRA. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 2007;26:115–123.17413976)| false
DanielAG, PetersWAIII. Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 1988;71:612–614.3353053)| false
SolimanPT, FrumovitzM, SpannuthW, et al.Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol2010;119:291–294.
SolimanPT, FrumovitzM, SpannuthW, Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists. Gynecol Oncol 2010;119:291–294.20708226)| false
KumarS, MarianiA, Bakkum-GamezJN, et al.Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol2013;130:441–445.
KumarS, MarianiA, Bakkum-GamezJN, Risk factors that mitigate the role of paraaortic lymphadenectomy in uterine endometrioid cancer. Gynecol Oncol 2013;130:441–445.23747331)| false
TodoY, KatoH, KaneuchiM, et al.Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet2010;375:1165–1172.
TodoY, KatoH, KaneuchiM, Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:1165–1172.20188410)| false
KitchenerH, SwartAM, QianQ, et al.Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet2009;373:125–136.
KitchenerH, SwartAM, QianQ, Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125–136.)| false
Benedetti PaniciP, BasileS, ManeschiF, et al.Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst2008;100:1707–1716.
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol2005;106:413–425.
American College of Obstetricians and Gynecologists. ACOG practice bulletin, clinical management guidelines for obstetrician-gynecologists, number 65, August 2005: management of endometrial cancer. Obstet Gynecol 2005;106:413–425.16055605)| false
Bodurtha SmithAJ, FaderAN, TannerEJ. Sentinel lymph node assessment in endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol2017;216:459–476.e10.
MarianiA, DowdySC, ClibyWA, et al.Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol2008;109:11–18.
HirahatakeK, HareyamaH, SakuragiN, et al.A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol1997;65:82–87.
HirahatakeK, HareyamaH, SakuragiN, A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol 1997;65:82–87.)| false
BarlinJN, Khoury-ColladoF, KimCH, et al.The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol2012;125:531–535.
BarlinJN, Khoury-ColladoF, KimCH, The importance of applying a sentinel lymph node mapping algorithm in endometrial cancer staging: beyond removal of blue nodes. Gynecol Oncol 2012;125:531–535.22366409)| false
BallesterM, KoskasM, CoutantC, et al.Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy?BMC Cancer2010;10:465.
BallesterM, KoskasM, CoutantC, Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy?BMC Cancer 2010;10:465.20804553)| false
HowJ, LauS, PressJ, et al.Accuracy of sentinel lymph node detection following intra-operative cervical injection for endometrial cancer: a prospective study. Gynecol Oncol2012;127:332–337.
Khoury-ColladoF, MurrayMP, HensleyML, et al.Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecol Oncol2011;122:251–254.
Khoury-ColladoF, MurrayMP, HensleyML, Sentinel lymph node mapping for endometrial cancer improves the detection of metastatic disease to regional lymph nodes. Gynecol Oncol 2011;122:251–254.21570109)| false
HollowayRW, Abu-RustumNR, BackesFJ, et al.Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol2017;146:405–415.
HollowayRW, Abu-RustumNR, BackesFJ, Sentinel lymph node mapping and staging in endometrial cancer: a Society of Gynecologic Oncology literature review with consensus recommendations. Gynecol Oncol 2017;146:405–415.28566221)| false
RossiEC, KowalskiLD, ScaliciJ, et al.A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol2017;18:384–392.
RossiEC, KowalskiLD, ScaliciJ, A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol 2017;18:384–392.)| false
PaleyPJ, VeljovichDS, PressJZ, et al.A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging. Am J Obstet Gynecol2016;215:117.E1–E7.
PaleyPJ, VeljovichDS, PressJZ, A prospective investigation of fluorescence imaging to detect sentinel lymph nodes at robotic-assisted endometrial cancer staging. Am J Obstet Gynecol 2016;215:117.E1–E7.)| false
RuscitoI, GasparriML, BraicuEI, et al.Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes-a meta-analysis. Ann Surg Oncol2016;23:3749–3756.
RuscitoI, GasparriML, BraicuEI, Sentinel node mapping in cervical and endometrial cancer: indocyanine green versus other conventional dyes-a meta-analysis. Ann Surg Oncol 2016;23:3749–3756.27160526)| false
FrumovitzM, PlanteM, LeePS, et al.Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol2018;19:1394–1403.
FrumovitzM, PlanteM, LeePS, Near-infrared fluorescence for detection of sentinel lymph nodes in women with cervical and uterine cancers (FILM): a randomised, phase 3, multicentre, non-inferiority trial. Lancet Oncol 2018;19:1394–1403.30143441)| false
RuizR, GorostidiM, JaunarenaI, et al.Maximizing sentinel node detection in endometrial cancer with dual cervical and transcervical fundal indocyanine green injection: 5-year single-center prospective study. Eur J Obstet Gynecol Reprod Biol2021;261:59–64.
BackesFJ, CohenD, SalaniR, et al.Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecol Oncol2019;153:496–499.
BackesFJ, CohenD, SalaniR, Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739). Gynecol Oncol 2019;153:496–499.31230614)| false
VidalF, LeguevaqueP, MottonS, et al.Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting. Int J Gynecol Cancer2013;23:1237–1243.
VidalF, LeguevaqueP, MottonS, Evaluation of the sentinel lymph node algorithm with blue dye labeling for early-stage endometrial cancer in a multicentric setting. Int J Gynecol Cancer 2013;23:1237–1243.)| false
Abu-RustumNR, Khoury-ColladoF, Pandit-TaskarN, et al.Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?Gynecol Oncol2009;113:163–169.
Abu-RustumNR, Khoury-ColladoF, Pandit-TaskarN, Sentinel lymph node mapping for grade 1 endometrial cancer: is it the answer to the surgical staging dilemma?Gynecol Oncol 2009;113:163–169.)| false
BallesterM, DubernardG, LécuruF, et al.Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol2011;12:469–476.
BallesterM, DubernardG, LécuruF, Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 2011;12:469–476.21489874)| false
TouhamiO, TrinhXB, GregoireJ, et al.Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol2015;138:41–45.
SolimanPT, WestinSN, DiounS, et al.A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol2017;146:234–239.
SolimanPT, WestinSN, DiounS, A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. Gynecol Oncol 2017;146:234–239.28528918)| false
KimCH, Khoury-ColladoF, BarberEL, et al.Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol2013;131:714–719.
KimCH, Khoury-ColladoF, BarberEL, Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion. Gynecol Oncol 2013;131:714–719.24099838)| false
CormierB, RozenholcAT, GotliebW, et al.Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol2015;138:478–485.
CormierB, RozenholcAT, GotliebW, Sentinel lymph node procedure in endometrial cancer: a systematic review and proposal for standardization of future research. Gynecol Oncol 2015;138:478–485.26047592)| false
HollowayRW, GuptaS, StavitzskiNM, et al.Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol2016;141:206–210.
HollowayRW, GuptaS, StavitzskiNM, Sentinel lymph node mapping with staging lymphadenectomy for patients with endometrial cancer increases the detection of metastasis. Gynecol Oncol 2016;141:206–210.26905211)| false
DaraïE, DubernardG, BatsAS, et al.Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol2015;136:54–59.
DaraïE, DubernardG, BatsAS, Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol 2015;136:54–59.25450151)| false
LeeJH, DubinskyT, AndreottiRF, et al.ACR Appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q2011;27:139–145.
LeeJH, DubinskyT, AndreottiRF, ACR Appropriateness Criteria pretreatment evaluation and follow-up of endometrial cancer of the uterus. Ultrasound Q 2011;27:139–145.21606818)| false
NaouraI, CanlorbeG, BendifallahS, et al.Relevance of sentinel lymph node procedure for patients with high-risk endometrial cancer. Gynecol Oncol2015;136:60–64.
SchiavoneMB, ZivanovicO, ZhouQ, et al.Survival of patients with uterine carcinosarcoma undergoing sentinel lymph node mapping. Ann Surg Oncol2016;23:196–202.
LecointreL, LodiM, FallerÉ, et al.Diagnostic accuracy and clinical impact of sentinel lymph node sampling in endometrial cancer at high risk of recurrence: a meta-analysis. J Clin Med2020;9:3874.
LecointreL, LodiM, FallerÉ, Diagnostic accuracy and clinical impact of sentinel lymph node sampling in endometrial cancer at high risk of recurrence: a meta-analysis. J Clin Med 2020;9:3874.33260511)| false
BoganiG, PapadiaA, BudaA, et al.Sentinel node mapping vs sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: results from a multi-institutional study. Gynecol Oncol2021;161:122–129.
BoganiG, PapadiaA, BudaA, Sentinel node mapping vs sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: results from a multi-institutional study. Gynecol Oncol 2021;161:122–129.33485641)| false
CusimanoMC, VicusD, PulmanK, et al.Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg2021;156:157–164.
CusimanoMC, VicusD, PulmanK, Assessment of sentinel lymph node biopsy vs lymphadenectomy for intermediate- and high-grade endometrial cancer staging. JAMA Surg 2021;156:157–164.33175109)| false
MarchockiZ, CusimanoMC, ClarfieldL, et al.Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol2021;225:367.E1–E39.
MarchockiZ, CusimanoMC, ClarfieldL, Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics. Am J Obstet Gynecol 2021;225:367.E1–E39.34058168)| false
EuscherE, SuiD, SolimanP, et al.Ultrastaging of sentinel lymph nodes in endometrial carcinoma according to use of 2 different methods. Int J Gynecol Pathol2018;37:242–251.
EuscherE, SuiD, SolimanP, Ultrastaging of sentinel lymph nodes in endometrial carcinoma according to use of 2 different methods. Int J Gynecol Pathol 2018;37:242–251.28700425)| false
BurgLC, HengeveldEM, in ‘t HoutJ, et al.Ultrastaging methods of sentinel lymph nodes in endometrial cancer - a systematic review. Int J Gynecol Cancer2021;31:744–753.
BurgLC, HengeveldEM, in ‘t HoutJ, Ultrastaging methods of sentinel lymph nodes in endometrial cancer - a systematic review. Int J Gynecol Cancer 2021;31:744–753.33187974)| false
KimCH, SoslowRA, ParkKJ, et al.Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer2013;23:964–970.
KimCH, SoslowRA, ParkKJ, Pathologic ultrastaging improves micrometastasis detection in sentinel lymph nodes during endometrial cancer staging. Int J Gynecol Cancer 2013;23:964–970.23694985)| false
RaimondE, BallesterM, HudryD, et al.Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study. Gynecol Oncol2014;133:506–511.
RaimondE, BallesterM, HudryD, Impact of sentinel lymph node biopsy on the therapeutic management of early-stage endometrial cancer: results of a retrospective multicenter study. Gynecol Oncol 2014;133:506–511.24642092)| false
AmezcuaCA, MacDonaldHR, LumCA, et al.Endometrial cancer patients have a significant risk of harboring isolated tumor cells in histologically negative lymph nodes. Int J Gynecol Cancer2006;16:1336–1341.
AmezcuaCA, MacDonaldHR, LumCA, Endometrial cancer patients have a significant risk of harboring isolated tumor cells in histologically negative lymph nodes. Int J Gynecol Cancer 2006;16:1336–1341.16803526)| false
TodoY, KatoH, OkamotoK, et al.Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. J Gynecol Oncol2016;27:e1.
TodoY, KatoH, OkamotoK, Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. J Gynecol Oncol 2016;27:e1.)| false
FrimerM, Khoury-ColladoF, MurrayMP, et al.Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation?Gynecol Oncol2010;119:496–499.
FrimerM, Khoury-ColladoF, MurrayMP, Micrometastasis of endometrial cancer to sentinel lymph nodes: is it an artifact of uterine manipulation?Gynecol Oncol 2010;119:496–499.20888626)| false
SmerageJB, BarlowWE, HortobagyiGN, et al.Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol2014;32:3483–3489.
OlawaiyeAB, MutchDG. Lymphnode staging update in the American Joint Committee on Cancer 8th edition cancer staging manual. Gynecol Oncol 2018;150:7–8.29540290)| false
St ClairCM, ErikssonAG, DucieJA, et al.Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol2016;23:1653–1659.
Gómez-HidalgoNR, RamirezPT, NgoB, et al.Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis. Clin Transl Oncol2020;22:1272–1279.
Gómez-HidalgoNR, RamirezPT, NgoB, Oncologic impact of micrometastases or isolated tumor cells in sentinel lymph nodes of patients with endometrial cancer: a meta-analysis. Clin Transl Oncol 2020;22:1272–1279.31863354)| false
ScaliciJ, LaughlinBB, FinanMA, et al.The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes. Gynecol Oncol2015;136:512–515.
ScaliciJ, LaughlinBB, FinanMA, The trend towards minimally invasive surgery (MIS) for endometrial cancer: an ACS-NSQIP evaluation of surgical outcomes. Gynecol Oncol 2015;136:512–515.25462206)| false
JandaM, GebskiV, DaviesLC, et al.Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA2017;317:1224–1233.
JandaM, GebskiV, DaviesLC, Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 2017;317:1224–1233.)| false
FaderAN, WeiseRM, SinnoAK, et al.Utilization of minimally invasive surgery in endometrial cancer care: a quality and cost disparity. Obstet Gynecol2016;127:91–100.
FaderAN, WeiseRM, SinnoAK, Utilization of minimally invasive surgery in endometrial cancer care: a quality and cost disparity. Obstet Gynecol 2016;127:91–100.)| false
GalaalK, BryantA, FisherAD, et al.Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev2012;9:CD006655.
GalaalK, BryantA, FisherAD, Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012;9:CD006655.)| false
KornblithAB, HuangHQ, WalkerJL, et al.Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol2009;27:5337–5342.
KornblithAB, HuangHQ, WalkerJL, Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:5337–5342.)| false
WalkerJL, PiedmonteMR, SpirtosNM, et al.Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP2. J Clin Oncol2009;27:5331–5336.
WalkerJL, PiedmonteMR, SpirtosNM, Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group study LAP2. J Clin Oncol 2009;27:5331–5336.)| false
MannschreckD, MatsunoRK, MoriartyJP, Disparities in surgical care among women with endometrial cancer. Obstet Gynecol 2016;128:526–534.27500330)| false
WalkerJL, PiedmonteMR, SpirtosNM, et al.Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol2012;30:695–700.
WalkerJL, PiedmonteMR, SpirtosNM, Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study. J Clin Oncol 2012;30:695–700.22291074)| false
MouritsMJ, BijenCB, ArtsHJ, et al.Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol2010;11:763–771.
MouritsMJ, BijenCB, ArtsHJ, Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial. Lancet Oncol 2010;11:763–771.20638901)| false
ReijntjesB, van SuijlichemM, WoolderinkJM, et al.Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: long-term outcomes of a randomised trial. Gynecol Oncol2022;164:265–270.
ReijntjesB, van SuijlichemM, WoolderinkJM, Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: long-term outcomes of a randomised trial. Gynecol Oncol 2022;164:265–270.34955237)| false
WangHL, RenYF, YangJ, et al.Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. Asian Pac J Cancer Prev2013;14:2515–2519.
WangHL, RenYF, YangJ, Total laparoscopic hysterectomy versus total abdominal hysterectomy for endometrial cancer: a meta-analysis. Asian Pac J Cancer Prev 2013;14:2515–2519.23725166)| false
ElSahwiKS, HooperC, De LeonMC, et al.Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecol Oncol2012;124:260–264.
ElSahwiKS, HooperC, De LeonMC, Comparison between 155 cases of robotic vs. 150 cases of open surgical staging for endometrial cancer. Gynecol Oncol 2012;124:260–264.22036203)| false
ChanJK, GardnerAB, TaylorK, et al.Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates. Gynecol Oncol2015;139:300–305.
ChanJK, GardnerAB, TaylorK, Robotic versus laparoscopic versus open surgery in morbidly obese endometrial cancer patients - a comparative analysis of total charges and complication rates. Gynecol Oncol 2015;139:300–305.26363212)| false
CoronadoPJ, HerraizMA, MagrinaJF, et al.Comparison of perioperative outcomes and cost of robotic-assisted laparoscopy, laparoscopy and laparotomy for endometrial cancer. Eur J Obstet Gynecol Reprod Biol2012;165:289–294.
BellMC, TorgersonJ, Seshadri-KreadenU, et al.Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques. Gynecol Oncol2008;111:407–411.
BellMC, TorgersonJ, Seshadri-KreadenU, Comparison of outcomes and cost for endometrial cancer staging via traditional laparotomy, standard laparoscopy and robotic techniques. Gynecol Oncol 2008;111:407–411.18829091)| false
Cardenas-GoicoecheaJ, AdamsS, BhatSB, et al.Surgical outcomes of robotic-assisted surgical staging for endometrial cancer are equivalent to traditional laparoscopic staging at a minimally invasive surgical center. Gynecol Oncol2010;117:224–228.
Cardenas-GoicoecheaJ, AdamsS, BhatSB, Surgical outcomes of robotic-assisted surgical staging for endometrial cancer are equivalent to traditional laparoscopic staging at a minimally invasive surgical center. Gynecol Oncol 2010;117:224–228.)| false
AbelMK, ChanJK, ChowS, et al.Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer. Int J Gynecol Cancer2020;30:1347–1355.
AbelMK, ChanJK, ChowS, Trends and survival outcomes of robotic, laparoscopic, and open surgery for stage II uterine cancer. Int J Gynecol Cancer 2020;30:1347–1355.32753561)| false
CapozziVA, RiemmaG, RosatiA, et al.Surgical complications occurring during minimally invasive sentinel lymph node detection in endometrial cancer patients. A systematic review of the literature and metanalysis. Eur J Surg Oncol2021;47:2142–2149.
CapozziVA, RiemmaG, RosatiA, Surgical complications occurring during minimally invasive sentinel lymph node detection in endometrial cancer patients. A systematic review of the literature and metanalysis. Eur J Surg Oncol 2021;47:2142–2149.33820674)| false
BrudieLA, BackesFJ, AhmadS, et al.Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. Gynecol Oncol2013;128:309–315.
BrudieLA, BackesFJ, AhmadS, Analysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery. Gynecol Oncol 2013;128:309–315.23153590)| false
BackesFJ, BrudieLA, FarrellMR, et al.Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol2012;125:546–551.
BackesFJ, BrudieLA, FarrellMR, Short- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging. Gynecol Oncol 2012;125:546–551.)| false
SiestoG, OrnaghiS, IedàN, et al.Robotic surgical staging for endometrial and cervical cancers in medically ill patients. Gynecol Oncol2013;129:593–597.
van DamP, HauspyJ, VerkinderenL, Are costs of robot-assisted surgery warranted for gynecological procedures?Obstet Gynecol Int 2011;2011:973830.21941556)| false
RamirezPT, AdamsS, BoggessJF, et al.Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Gynecol Oncol2012;124:180–184.
RamirezPT, AdamsS, BoggessJF, Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Gynecol Oncol 2012;124:180–184.22079679)| false
American Congress of Obstetricians and Gynecologists. Statement on Robotic Surgery by ACOG President James T. Breeden. Accessed December 20, 2022. Available at: http://www.acog.org/About-ACOG/News-Room/News-Releases/2013/Statement-on-Robotic-Surgery)| false
GalaRB, MarguliesR, SteinbergA, et al.Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy. J Minim Invasive Gynecol2014;21:353–361.
GalaRB, MarguliesR, SteinbergA, Systematic review of robotic surgery in gynecology: robotic techniques compared with laparoscopy and laparotomy. J Minim Invasive Gynecol 2014;21:353–361.24295923)| false
Society of Gynecologic Onconlogy. SGO position statement: morcellation. Accessed September 30, 2014. Available at: https://www.sgo.org/newsroom/position-statements-2/morcellation/25797958)| false
ACOG. Power morcellation and occult malignancy in gynecologic surgery. Accessed January 23, 2023. Available at: https://www.sgo.org/wp-content/uploads/2014/04/ACOG_Statement.pdf)| false
U.S. Department of Health and Human Services. FDA discourages use of laparoscopic power morcellation for removal of uterus or uterine fibroids. Accessed January 23, 2023. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm393689.htm)| false
BoganiG, ClibyWA, AlettiGD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol2015;137:167–172.
BoganiG, ClibyWA, AlettiGD. Impact of morcellation on survival outcomes of patients with unexpected uterine leiomyosarcoma: a systematic review and meta-analysis. Gynecol Oncol 2015;137:167–172.25462199)| false
WrightJD, BuckAM, ShahM, Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27:1214–1219.19171707)| false
KoskasM, BendifallahS, LutonD, et al.Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril2012;98:1229–1235.
KoskasM, BendifallahS, LutonD, Safety of uterine and/or ovarian preservation in young women with grade 1 intramucous endometrial adenocarcinoma: a comparison of survival according to the extent of surgery. Fertil Steril 2012;98:1229–1235.22959452)| false
LeeTS, LeeJY, KimJW, et al.Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. Gynecol Oncol2013;131:289–293.
LeeTS, LeeJY, KimJW, Outcomes of ovarian preservation in a cohort of premenopausal women with early-stage endometrial cancer: a Korean Gynecologic Oncology Group study. Gynecol Oncol 2013;131:289–293.)| false
ManfrediR, MirkP, MarescaG, Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning. Radiology 2004;231:372–378.15031434)| false
GundersonCC, FaderAN, CarsonKA, et al.Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol2012;125:477–482.
GundersonCC, FaderAN, CarsonKA, Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012;125:477–482.22245711)| false
BakerJ, ObermairA, GebskiV, et al.Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol2012;125:263–270.
BakerJ, ObermairA, GebskiV, Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012;125:263–270.22196499)| false
UshijimaK, YahataH, YoshikawaH, et al.Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol2007;25:2798–2803.
UshijimaK, YahataH, YoshikawaH, Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798–2803.17602085)| false
HubbsJL, SaigRM, AbaidLN, et al.Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol2013;121:1172–1180.
HubbsJL, SaigRM, AbaidLN, Systemic and local hormone therapy for endometrial hyperplasia and early adenocarcinoma. Obstet Gynecol 2013;121:1172–1180.23812449)| false
HahnHS, YoonSG, HongJS, et al.Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer2009;19:1068–1073.
HahnHS, YoonSG, HongJS, Conservative treatment with progestin and pregnancy outcomes in endometrial cancer. Int J Gynecol Cancer 2009;19:1068–1073.19820370)| false
ParkJY, KimDY, KimJH, et al.Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer2013;49:868–874.
ParkJY, KimDY, KimJH, Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer 2013;49:868–874.23072814)| false
BiQ, BiG, WangJ, et al.Diagnostic accuracy of MRI for detecting cervical invasion in patients with endometrial carcinoma: a meta- analysis. J Cancer2021;12:754–764.
BiQ, BiG, WangJ, Diagnostic accuracy of MRI for detecting cervical invasion in patients with endometrial carcinoma: a meta- analysis. J Cancer 2021;12:754–764.33403033)| false
BiQ, ChenY, WuK, et al.The diagnostic value of MRI for preoperative staging in patients with endometrial cancer: a meta-analysis. Acad Radiol2020;27:960–968.
BiQ, ChenY, WuK, The diagnostic value of MRI for preoperative staging in patients with endometrial cancer: a meta-analysis. Acad Radiol 2020;27:960–968.31636004)| false
BoenteMP, YordanELJr, McIntoshDG, et al.Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol1993;51:316–322.
SartoriE, GadducciA, LandoniF, et al.Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer2001;11:430–437.
SartoriE, GadducciA, LandoniF, Clinical behavior of 203 stage II endometrial cancer cases: the impact of primary surgical approach and of adjuvant radiation therapy. Int J Gynecol Cancer 2001;11:430–437.11906545)| false
LambrouNC, Gómez-MarínO, MirhashemiR, et al.Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol2004;93:653–658.
LambrouNC, Gómez-MarínO, MirhashemiR, Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 2004;93:653–658.15196860)| false
AlbrightBB, MonuszkoKA, KaplanSJ, et al.Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol2021;225:237.e1–237.e24.
AlbrightBB, MonuszkoKA, KaplanSJ, Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis. Am J Obstet Gynecol 2021;225:237.e1–237.e24.33957111)| false
PalmaDA, OlsonR, HarrowS, et al.Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet2019;393:2051–2058.
PalmaDA, OlsonR, HarrowS, Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019;393:2051–2058.30982687)| false
GadducciA, CosioS, GenazzaniAR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol2006;58:242–256.
GadducciA, CosioS, GenazzaniAR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006;58:242–256.)| false
FishmanDA, RobertsKB, ChambersJT, et al.Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol1996;61:189–196.
FishmanDA, RobertsKB, ChambersJT, Radiation therapy as exclusive treatment for medically inoperable patients with stage I and II endometrioid carcinoma with endometrium. Gynecol Oncol 1996;61:189–196.)| false
NiaziTM, SouhamiL, PortelanceL, et al.Long-term results of high-dose-rate brachytherapy in the primary treatment of medically inoperable stage I-II endometrial carcinoma. Int J Radiat Oncol Biol Phys2005;63:1108–1113.
van der Steen-BanasikE, ChristiaensM, ShashE, et al.Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer2016;65:172–181.
van der Steen-BanasikE, ChristiaensM, ShashE, Systemic review: radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 2016;65:172–181.27501506)| false
RandallME, FiliaciVL, MussH, et al.Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol2006;24:36–44.
RandallME, FiliaciVL, MussH, Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2006;24:36–44.)| false
HomesleyHD, FiliaciV, GibbonsSK, et al.A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol2009;112:543–552.
HomesleyHD, FiliaciV, GibbonsSK, A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol 2009;112:543–552.19108877)| false
SecordAA, HavrileskyLJ, O’MalleyDM, et al.A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol2009;114:442–447.
SecordAA, HavrileskyLJ, O’MalleyDM, A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer. Gynecol Oncol 2009;114:442–447.19560193)| false
CreutzbergCL, van StiphoutRG, NoutRA, et al.Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys2015;91:530–539.
CreutzbergCL, van StiphoutRG, NoutRA, Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials. Int J Radiat Oncol Biol Phys 2015;91:530–539.)| false
KloppA, SmithBD, AlektiarK, et al.The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol2014;4:137–144.
KloppA, SmithBD, AlektiarK, The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2014;4:137–144.24766678)| false
MeyerLA, BohlkeK, PowellMA, et al.Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline. J Clin Oncol2015;33:2908–2913.
MeyerLA, BohlkeK, PowellMA, Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology evidence-based guideline. J Clin Oncol 2015;33:2908–2913.)| false
NeubauerNL, HavrileskyLJ, CalingaertB, et al.The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol2009;112:511–516.
NeubauerNL, HavrileskyLJ, CalingaertB, The role of lymphadenectomy in the management of preoperative grade 1 endometrial carcinoma. Gynecol Oncol 2009;112:511–516.19144394)| false
GretzHFIII, EconomosK, HusainA, et al.The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol1996;61:409–415.
GretzHFIII, EconomosK, HusainA, The practice of surgical staging and its impact on adjuvant treatment recommendations in patients with stage I endometrial carcinoma. Gynecol Oncol 1996;61:409–415.)| false
NoutRA, SmitVT, PutterH, et al.Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet2010;375:816–823.
NoutRA, SmitVT, PutterH, Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816–823.20206777)| false
ElshaikhMA, Al-WahabZ, MahdiH, et al.Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol2015;136:235–239.
ElshaikhMA, Al-WahabZ, MahdiH, Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. Gynecol Oncol 2015;136:235–239.25511158)| false
CreutzbergCL, van PuttenWL, KoperPC, et al.Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet2000;355:1404–1411.
CreutzbergCL, van PuttenWL, KoperPC, Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet 2000;355:1404–1411.10791524)| false
AaldersJ, AbelerV, KolstadP, et al.Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol1980;56:419–427.
AaldersJ, AbelerV, KolstadP, Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419–427.)| false
KeysHM, RobertsJA, BrunettoVL, et al.A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol2004;92:744–751.
KeysHM, RobertsJA, BrunettoVL, A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004;92:744–751.14984936)| false
CreutzbergCL, van PuttenWL, Wárlám-RodenhuisCC, et al.Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol2004;22:1234–1241.
CreutzbergCL, van PuttenWL, Wárlám-RodenhuisCC, Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004;22:1234–1241.)| false
ScholtenAN, van PuttenWL, BeermanH, et al.Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys2005;63:834–838.
ScholtenAN, van PuttenWL, BeermanH, Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834–838.15927414)| false
BlakeP, SwartAM, OrtonJ, et al.Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet2009;373:137–146.
BlakeP, SwartAM, OrtonJ, Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009;373:137–146.19070891)| false
CreutzbergCL, NoutRA, LybeertML, et al.Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys2011;81:e631–638.
SmallWJr, BeriwalS, DemanesDJ, et al.American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy2012;11:58–67.
SmallWJr, BeriwalS, DemanesDJ, American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy 2012;11:58–67.22265439)| false
NoutRA, PutterH, Jürgenliemk-SchulzIM, et al.Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer2012;48:1638–1648.
NoutRA, PutterH, Jürgenliemk-SchulzIM, Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2012;48:1638–1648.22176868)| false
RöperB, AstnerST, Heydemann-ObradovicA, et al.Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol2007;107:541–548.
RöperB, AstnerST, Heydemann-ObradovicA, Ten-year data on 138 patients with endometrial carcinoma and postoperative vaginal brachytherapy alone: no need for external-beam radiotherapy in low and intermediate risk patients. Gynecol Oncol 2007;107:541–548.17884152)| false
NoutRA, PutterH, Jürgenliemk-SchulzIM, et al.Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol2009;27:3547–3556.
NoutRA, PutterH, Jürgenliemk-SchulzIM, Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27:3547–3556.19546404)| false
McCloskeySA, TchaboNE, MalhotraHK, et al.Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol2010;116:404–407.
McCloskeySA, TchaboNE, MalhotraHK, Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation. Gynecol Oncol 2010;116:404–407.19944453)| false
DunnEF, GeyeH, PlattaCS, et al.Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer. Gynecol Oncol2014;133:494–498.
DunnEF, GeyeH, PlattaCS, Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer. Gynecol Oncol 2014;133:494–498.)| false
NarasimhuluDM, CopeA, RiazIB, et al.External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer2020;30:797–805.
NarasimhuluDM, CopeA, RiazIB, External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2020;30:797–805.32221021)| false
RandallME, FiliaciV, McMeekinDS, et al.Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol2019;37:1810–1818.
RandallME, FiliaciV, McMeekinDS, Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol 2019;37:1810–1818.30995174)| false
ChinoJP, JonesE, BerchuckA, et al.The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys2012;82:1872–1879.
ChinoJP, JonesE, BerchuckA, The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer. Int J Radiat Oncol Biol Phys 2012;82:1872–1879.21640502)| false
LeeCM, SzaboA, ShrieveDC, et al.Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA2006;295:389–397.
LeeCM, SzaboA, ShrieveDC, Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295:389–397.)| false
JohnsonN, CornesP. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG2007;114:1313–1320.
JohnsonN, CornesP. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007;114:1313–1320.17803718)| false
KongA, JohnsonN, KitchenerHC, et al.Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst2012;104:1625–1634.
KongA, JohnsonN, KitchenerHC, Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012;104:1625–1634.)| false
EifelPJ. The role of adjuvant radiation therapy for stage I endometrial cancer: does meta-analysis reveal the answer?J Natl Cancer Inst2012;104:1615–1616.
EifelPJ. The role of adjuvant radiation therapy for stage I endometrial cancer: does meta-analysis reveal the answer?J Natl Cancer Inst 2012;104:1615–1616.)| false
ParkHJ, NamEJ, KimS, et al.The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol2013;170:39–44.
ParkHJ, NamEJ, KimS, The benefit of adjuvant chemotherapy combined with postoperative radiotherapy for endometrial cancer: a meta-analysis. Eur J Obstet Gynecol Reprod Biol 2013;170:39–44.23810000)| false
HogbergT, SignorelliM, de OliveiraCF, et al.Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer2010;46:2422–2431.
HogbergT, SignorelliM, de OliveiraCF, Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. Eur J Cancer 2010;46:2422–2431.20619634)| false
SecordAA, GellerMA, BroadwaterG, et al.A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol2013;128:65–70.
SecordAA, GellerMA, BroadwaterG, A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. Gynecol Oncol 2013;128:65–70.23085460)| false
